Piper Sandler Reiterates Overweight on TransMedics Group, Lowers Price Target to $100

Benzinga Newsdesk www.benzinga.com Negative 91.5%

Neg 91.5% Neu 0% Pos 0%

Piper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:TMDX) with a Overweight and lowers the price target from $120 to $100.